Protocol Ledger

NCT04083235 · Phase III · COMPLETED

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+

Interventional Phase III clinical trial protocol NCT04083235 sponsored by Ipsen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-02-11 Enrollment: 770 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04083235
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)770 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04083235
Protocol FieldVerified Registry Value
NCT IdentifierNCT04083235
Consolidated Lead SponsorIpsen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment770 participants (ACTUAL)
Registered Start Date2020-02-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI